Elis­a­bet de los Pinos and her team fu­el up for a late-stage quest to de­liv­er a safe eye can­cer drug

Since its found­ing in 2009, Au­ra Bio­sciences has been laser-fo­cused on cre­at­ing a safer al­ter­na­tive to cur­rent­ly avail­able eye can­cer ther­a­pies. And on Mon­day, the biotech pulled in $80 mil­lion to walk its lead can­di­date to Phase III.

The Se­ries E round brings the Cam­bridge, MA-based com­pa­ny’s to­tal raise to over $200 mil­lion. The biotech will use the funds for its virus-like drug con­ju­gates, in­clud­ing its lead can­di­date, AU-011,  which is head­ed for a piv­otal late-stage study in choroidal (oc­u­lar) can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.